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EXPRESSION OF PROTECTIVE ANTIGENS 
IN TRANSGENIC CHLOROPLASTS 
BACKGROUND 
Yersinia pestis is the causative agent of bubonic and 
pneumonic plague. Bacillus anthracis is the causative agent 
for the anthrax disease. The Centers for Disease Control and 
Prevention (hereinafter "CDC") lists Y. pestis and B. anthra-
cis as two of the six Category A biological agents that pose 
a risk to national security. 
Yersinia pestis 
The etiologic agent of plague is the Gram-negative bac-
terium Yersinia pestis. The natural route of transmission of 
Y. pestis from one animal host to another is either directly or 
via a flea vector. Plague is endemic in some regions of the 
world and outbreaks occasionally occur as a consequence of 
natural disasters. Y. pestis is also a concern as one of the 
microorganisms with potential for use against civilian or 
military populations as a biological warfare/biological ter-
rorism agent. In such a situation, the pneumonic form of 
plague would be the most likely outcome. This form of 
plague is particularly devastating because of the rapidity of 
onset, the high mortality, and the rapid spread of the disease. 
Immunization against aerosolized plague presents a particu-
lar challenge for vaccine developers. There is currently no 
vaccine for plague. 
Both live attenuated and killed plague vaccines have been 
used in man, although questions remain about their safety 
and relative efficacy, especially against the pneumonic form 
of infection. Since plague remains endemic in some regions 
of the world, and because of the possibility of the illegiti-
mate use of Y. pestis as a biological warfare agent, devel-
opment of improved vaccines against plague is a high 
priority. The ideal vaccine should be deliverable in a mini-
mum of doses and quickly produce high titer and long-
lasting antibodies. Moreover, such a vaccine should protect 
against aerosolized transmission of Y. pestis. 
The two most recently described approaches to develop-
ment of improved plague vaccines are 1) attenuated mutants 
of Y. pestis and 2) subunit vaccines. The potential efficacy of 
attenuated mutants of Y. pestis as vaccines is supported by 
experience with the live attenuated vaccine strain EV76. 
This vaccine has been in use since 1908 and is given as a 
single dose Immunization of mice with EV76 induces an 
immune response and protects mice against subcutaneous 
and inhalation (aerosolized) infection. However, this vac-
cine strain is not avirulent and has an unacceptable safety 
profile. Moreover, multiple variants of the classical EV76 
strain exist that differ significantly in passage history and 
genetic characteristics. Recent studies have focused on cre-
ating defined genetically attenuated mutants of Y. pestis, 
similar to those created in other Gram-negative bacteria (i.e., 
Salmonella spp.). For unknown reasons, genetic mutations, 
which markedly attenuate Salmonella spp. do not attenuate 
Y. pestis. For instance, an aroA mutant of Y. pestis was fully 
virulent in the murine model of disease but avirulent in 
guinea pigs. 
A number of potential subunit vaccines have been evalu-
ated for immunogenicity and protective efficacy against Y. 
pestis. The two most promising are Fl and V. Fl is a capsular 
protein located on the surface of the bacterium and the V 
antigen is a component of the Y. pestis Type III secretion 
system. These proteins have been produced recombinantly 
and induce protective immune responses when administered 
individually. A combination or fusion of F 1 and V may have 
2 
an additive protective effect when used to immunize humans 
against plague. It is thought that Fl-V fusion protein should 
provide protection against both subcutaneous and aerosol 
challenge, and will have the potential to provide protective 
immunity against pneumonic as well as bubonic plague due 
to either wild type Fl+ Y. pestis or to naturally occurring 
Fl-variants. To date no one has been able to express the 
Fl-V fusion protein in transgenic chloroplast. Such an 
accomplishment would provide a large supply of high-
10 quality antigen for vaccines. 
Bacillus anthracis 
Bacillus anthracis is the organism that causes the anthrax 
disease. It is a Gram-positive, nonmotile, aerobic or facul-
15 tatively anaerobic, spore-forming bacterium. The spores are 
about 1 µm in size, extremely hardy, resistant to ganima 
rays, UV light, drying, heat, and many disinfectants. Spores 
germinate upon entering an environment rich in glucose, 
amino acids, and nucleosides, such as in animal and human 
20 tissues and blood. The vegetative cells enter the spore state 
when the nutrients are exhausted or when the organisms are 
exposed to molecular oxygen in the air. 
Anthrax is typically a disease of animals, especially 
herbivores such as cows, sheep, and goats. It affects humans 
25 through contact with the spores in one of three ways. 
Cutaneous anthrax occurs when the spores enter the body 
through a cut or an abrasion on the skin. Gastrointestinal 
anthrax occurs when the spores enters the body through 
consumption of contaminated meat products. Inhalation 
30 anthrax occurs when the spores enter the body through 
inhalation of the spores. 
When spores enter the body, macrophages engulf them, 
migrate to regional lymph nodes and the spores germinate 
into vegetative bacteria. Macrophages release the vegetative 
35 bacteria and they spread through the blood and lymph until 
there are up to 108 bacilli per milliliter of blood. The 
exotoxins are produced from bacteria and they lead to 
symptoms and possible death. Spores can survive in the 
lungs or lymph nodes up to 60 days before germination 
40 occurs. In animal experiments, it has been seen that once 
toxin secretion has reached a critical threshold, death will 
occur, even if the blood is rendered sterile through the use 
of antibiotics. From primate studies, the estimated lethal 
dose of inhaled anthrax spores sufficient to kill 50% of 
45 humans exposed to it (the LD50) is 2,500-55,000 spores. 
The CDC lists anthrax as a category A disease agent and 
estimates the cost of an anthrax attack would be $26.2 
billion per 100,000 persons exposed. The only vaccine 
licensed for human use in the U.S., Biothrax (formerly 
50 Anthrax vaccine adsorbed, or AVA), is an aluminum hydrox-
ide-adsorbed, formalin-treated culture supernatant of a toxi-
genic, nonencapsulated, non-proteolytic strain of Bacillus 
anthracis. In addition to the immunogenic protective antigen 
(PA), the vaccine contains trace amounts of edema factor 
55 (EF) and lethal factor (LF) that may contribute to the local 
reactions seen in 5-7% of vaccine recipients, or reported to 
be toxic causing side-effects. There is a clear need and 
urgency for an improved vaccine for anthrax and for 
improved production methods that allow it to be mass-
60 produced at reasonable cost. 
There are two main virulence factors associated with B. 
anthracis, the polyglutamyl capsule which is believed to 
prevent the vegetative bacterial cells from being phagocy-
tized and the exotoxins. Two different exotoxins are pro-
65 duced by three factors. PA binds to the host cell, LF is a zinc 
metalloprotease which inactivates mitogen-activated protein 
kinase. The edema toxin is formed when PA binds to EF. 
US 7,354,760 B2 
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This toxin increases cyclic AMP ( cAMP) levels in the cell 
which upsets the water homeostasis resulting in accumula-
tion of fluid called edema. The lethal toxin is formed from 
binding of PA and LF. This toxin stimulates macrophages to 
release interleukin-I b, tumor necrosis factor a, and other 5 
cytokines which contribute to shock and sudden death. 
Anthrax has become a serious threat due to its potential 
use in bioterrorism and recent outbreaks among wild-life in 
the United States. Concerns regarding vaccine purity, the 
current requirement for six injections followed by yearly 10 
boosters, and a limited supply of the key protective antigen 
(PA), underscore the urgent need for an improved vaccine. 
SUMMARY OF THE INVENTION 
4 
supernatant fraction, "Hom" means homogenate (soluble 
and insoluble fractions). The construct used was pLD-JW2. 
FIG. 4 shows western blots of T 1 pLD-JWl plant in 
continuous light in FIGS. 4A and 4B, and in FIG. 4C shows 
histogram of µg PA/g fresh tissue in young, mature, and old 
leaves after 3 and 5 days of continuous illumination. 
FIG. S shows graphs of the results of macrophage cyto-
toxic assays for extracts from transgenic plants. FIG. SA 
shows supernatant and homogenate samples from T 0 pLD-
JWl tested. FIG. SB shows Supernatant samples from T 1 
pLD-JWl tested. 
FIG. 6A is a schematic view of tomato vector construct 
pLD Tom-BADH, while FIG. 6B shows PCR for transfor-
mants using 3P/3M primers of the pLD-TOM-BADH 
15 tomato vector. 
The present invention pertains to vaccines for conferring 
immunity in mammals to infective pathogens, as well as 
vectors and methods for plastid transformation of plants to 
produce protective antigens and vaccines for oral delivery. 
The invention further provides transformed plastids having 20 
the ability to survive selection in both the light and the dark, 
at different developmental stages by using genes coding for 
two different enzymes capable of detoxifying the same 
selectable marker, driven by regulatory signals that are 
functional in proplastids as well as in mature chloroplasts. 25 
The invention utilizes antibiotic-free selectable markers to 
provide edible vaccines for conferring immunity to a mam-
mal against Bacillus anthracis, as well as Yersina pestis. The 
vaccines are operative by parenteral administration as well. 
The invention also extends to the transformed plants, plant 30 
parts, and seeds and progeny thereof. The invention is 
applicable to monocot and dicot plants. 
FIG. 7 is a schematic of the pTOM-BADH2-G10-pag 
tomato vector construct 
FIG. 8 shows PCR analysis of the products of tomato 
vectors using BADH primers, wherein+ is pTOM-GlO-PA 
vector control, - is WT Tomato plant, and # 3 is transgenic 
tomato plant. 
FIG. 9A shows tomato seedlings 12 days after seed 
germination, while 9B shows tomato cotyledons ready for 
bombardment. 
FIG. 10 shows cut and bombarded cotyledons. 
FIGS. llAand B show the response of tomato cotyledons 
transformed with the pLD-TOM-BADH on RMOP supple-
mented with 2.5 nm betaine aldehyde, where wild type is 
illustrated in lla and putative transformant in llb. 
FIG.12 shows the serum anti-PA as determined by ELISA 
and the in vitro toxin neutralization by serum antibodies 
following intranasal immunization. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 13A is a schematic view of a pLDS-FlV vector 
construct, while FIG. 13B shows restriction enzyme analysis 
35 of the pLDS-Fl V vector. 
FIG. 1 is a schematic view of anthrax chloroplast con-
structs according to the present invention, and a view of a 
southern blot. FIG. lA shows the pLD-JWl vector used for 
chloroplast transformation. FIG. lB shows the pLD-JW2 
construct. FIG. lC shows PCR with the primers 3P and 3M. 40 
FIG. lD shows a PCR analysis of randomly selected clones. 
FIG. 14A shows PCR reactions to determine pLDS-FlV 
vector integration into the chloroplast genome of Petit 
Havana, while 14B shows a second PCR reaction, which is 
also used to determine pLDS-Fl V transgene integration. 
FIG. lSA shows a Western Blot of pLDS-FlV from 
XLl-Blue strain of Ecoli, while lSB shows Western Blots of 
FlV expression in transgenic chloroplasts. FIG. 2 is a schematic view of anthrax chloroplast con-
structs according to the present invention, and views of 
southern blots. FIG. 2A shows expected products from 
digestion of wild type untransformed plant. FIG. 2B shows 
expected products from digestion of a plant transformed 
with pLD-JWl. FIG. 2C shows expected products from 
digestion of a plant transformed with pLD-JW2. FIG. 2D 
shows a flanking sequence probe showing heteroplasmy in 
pLD-JWl line and homoplasmy in pLD-JW2 lines. FIG. 2E 
shows a pag sequence probe showing presence of pag in 
transgenic lines. 
FIG. 3 shows Western blots demonstrating PA expression 
FIG. 16 is a schematic of constructs to be inserted in 
edible plants, where "gene X" represents each of LF27-
45 PA63, CTB-LF27, LF27-PA63+CTB-LF27, LF27+PA. 
FIG. 17A is a schematic view of a pDD34-ZM-gfp-
BADH vector construct, while 17B shows the subsequent 
expression of the construct containing GFP in E.coli, 
FIG. 18A is a schmetactic of pDD33-ZM-aadA-BADH 
50 vector construction, and 18B shows the subsequent expres-
sion of the construct in E.coli grown on spectinomycin. 
of transgenic lines containing different constructs. FIG. 3A 
shows a western blot of pLD-JWl T 1 transgenic lines for PA 55 
quantification. Lane 1: wild type; Lane 2: Ladder; Lane 3: 20 
FIG. 19(A-C) show GFP expression in embryogenic 
maize cultures where a is non-transgenic control and b and 
c are transformed maize embryonic calli. 
FIG. 20A shows maize control and transgenic plants on 
regeneration medium containing spectomycin, while FIG. 
20B shows PCR confirmation of chloroplast transgenic 
plants using appropriate primers. 
ng PA; Lane 4: 10 ng PA; Lane 5: 5 ng PA; Lane 6: 1:10 
dilution pLD-JWl line; Lane 7: 1 :20 dilution pLD-JWl line. 
FIG. 3B shows a western blot of pLD-JW2 T 1 transgenic 
lines for PA quantification. Lane 1: wild type; Lane 2: 
Ladder; Lane 3: 20 ng PA; Lane 4: 10 ng PA; Lane 5: 5 ng 
PA; Lane 6: blank; Lane 7: 1:10 dilution pLD-JW2 line #1; 
Lane 8: 1:20 dilution pLD-JW2 line #1; Lane 9: 1:10 
dilution pLD-JW2 line #2; Lane 10: 1 :20 dilution pLD-JW2 
line #2. FIG. 3C shows a western blot comparing extraction 
buffers, containing CHAPS and SDS, and both, and mea-
suring stability of extracts at 4 ° C., where "Sup" means 
FIG. 21Ais a schematic view ofa pDD37-DC-gfp-BADH 
60 carrot chloroplast transformation vector, while 21B illus-
trates GFP expression in E.coli. 
FIG. 22A is a schematic of a vector construct pDD36-DC 
aadA-BADH carrot chloroplast transformation vector, while 
22B illustrates the expression of the vector using E.coli cells 
65 grown on spectinomycin. 
FIG. 23 (A-D) shows Expression of GFP in different 
stages of transgenic cultures of carrot. 
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FIG. 24 is a schematic view of a Double Barreled Plastid 
Vector harboring aphA-6 and aphA-2 genes conferring resis-
tance to aminoglycosides according to the present invention. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Chloroplast Engineering 
6 
plasts. Chloroplasts are prokaryotic in nature and express 
native bacterial genes (like B subunit of cholera toxin) at 
very high levels (410-fold higher than nuclear expression). 
Production in chloroplasts is in sharp contrast to nuclear 
expression, that often requires extensive codon modifica-
tions because of high AT content, unfavorable codons, 
presence of mRNA destabilizing sequences, and cryptic 
polyadenylation or splice sites. Chloroplast transformation 
typically utilizes two flanking sequences that, through The concept of chloroplast genetic engineering, allows 
the introduction of isolated intact chloroplasts into proto-
plasts and regeneration of transgenic plants. Early investi-
gations involving chloroplast transformation focused on the 
development of in organello systems using intact chloro-
plasts capable of efficient and prolonged transcription, trans-
lation, and expression of foreign genes in isolated chloro-
plasts. However, the discovery of the gene gun as a 
transformation device made it possible to transform plant 
chloroplasts without the use of isolated plastids and proto-
plasts. Chloroplast genetic engineering has been accom-
plished in several phases. Studies have been made on the 
transient expression of foreign genes in plastids of monocots 
and dicots. Unique to the chloroplast genetic engineering is 
the development of a foreign gene expression system using 
autonomously replicating chloroplast expression vectors. 
Stable integration of a selectable marker gene into the 
tobacco chloroplast genome was also accomplished using 
the gene gun. Recently, useful genes conferring valuable 
traits via chloroplast genetic engineering have been demon-
strated. Plants resistant to Bacillus thuringiensis (Bt) sensi-
tive and resistant insects were obtained by integrating the 
cryIAc and cry2A genes into the tobacco chloroplast 
genome. 
10 homologous recombination, insert transgenes into spacer 
regions between functional genes of the chloroplast genome, 
thus targeting transgenes to a known location. This elimi-
nates the "position effect" and gene silencing frequently 
observed in nuclear transgenic plants. Chloroplast genetic 
15 engineering is an environmentally friendly approach, mini-
mizing concerns of out-cross of introduced traits via pollen 
to weeds or other related crops. The chloroplast genome may 
be engineered without the use of antibiotic resistant genes as 
well for the development of edible vaccines. The term 
20 "edible vaccine" as used herein refers to a substance which 
may be given orally which will elicit a protective immuno-
genic response in a manmial. 
25 
30 
The difficulty of engineering the chloroplast genome 
without antibiotic resistant genes has recently been over-
come by modifying chloroplasts without these genes. Engi-
neering genetically modified crops without these genes 
eliminates their potential transfer to the environment and to 
microbes in the gut. Antibiotic-free selection can be accom-
plished by using the betaine aldehyde dehydrogenase 
(BADH) gene from spinach as a selectable marker. Specifi-
Chloroplast genomes of plants have also been genetically 
engineered to confer herbicide resistance where the intro-
duced foreign genes were maternally inherited. This was a 
significant step in the development of commercially viable 
genetically modified plants because it alleviates any con-
cerns over the problem of out-crossing traits with weeds or 
other crops. 
cally, the Applicant's published application, WOOl/64023, 
which is hereby incorporated by reference, demonstrates 
using an antibiotic free selectable marker. The selection 
process involves conversion of toxic betaine aldehyde (BA) 
35 to non-toxic glycine betaine, which also serves as an osmo-
protectant and helps confer drought tolerance. 
The Applicant has transformed the chloroplast of edible 
monocot and dicot species, as is illustrated in the accompa-
40 nying Figures. Specifically, the figures illustrate the stable 
transformation of carrot and corn chloroplast genomes, 
which has not previously been accomplished. The transfor-
mation of carrot, tomato, and corn allow the production of 
edible vaccines. These transformed plants also allow the 
For large-scale foreign protein production, plants are an 
ideal choice due to the relative ease of genetic manipulation, 
rapid scale up (million seeds per plant), large biomass, and 
the potential to find alternative uses for various crops. A 
remarkable feature of chloroplast genetic engineering is the 
observation of exceptionally large accumulation of foreign 
proteins in transgenic plants (as much as 46% of CRY 
protein in total soluble protein) even in bleached old leaves. 
Using chloroplast transformation technology, large quanti-
ties of protective antigen can be produced in transgenic 50 
plants, due to the presence of thousands of copies of 
transgenes per cell as opposed to only a few copies in 
nuclear transgenic plants. By "protective antigen" is meant 
that the antigen elicits an immunogenic response in mam-
mals when administered by an appropriate route in an 55 
appropriate amount. Transgenic chloroplast technology has 
been used to hyper-express bacterial proteins-up to 46% of 
total soluble protein from Bacillus genes, the highest ever 
reported in transgenic plants. However, large heterologous 
proteins are not always processed correctly. Furthermore, 60 
such proteins are subject to attack by proteolytic enzymes 
after formation. The cholera toxin B subunit is about 11 
kilodaltons in size. The anthrax protective antigen is about 
45 purification and use of the antigens produced by these plants 
as high purity parenteral vaccines. However, the production 
of edible vaccines is preferred for their ease of use and low 
cost. 
83 kd in size, presenting a significant challenge to produc-
tion in a chloroplast. A similar challenge is presented by the 65 
F 1-V antigen, which is a fusion protein. Such fusion proteins 
have not heretofore been successfully expressed in chloro-
FIGS. 17 A and 18A illustrate the construction of maize 
chloroplast transformation vector, where flanking regions 
were amplified using PCR. The PCR products were cloned 
and the expression cassette was inserted in the transcrip-
tionally active spacer region between trnI/trnA genes. The 
expression cassette of FIG. 17A has the Prrn promoter 
driving the expression of GFP and BADH, which are regu-
lated by (5') gene10/rps16 3' and psbA 5'/3' UTRs respec-
tively. The expression cassette of 18A has the Prrn promoter 
driving the expression of aadA and BADH. The latter gene 
is regulated by (5') gene10/rps16 3' UTRs. 
Functions of the genes in the carrot chloroplast transfor-
mation vectors were tested in E. coli. For observing GFP 
expression, cells were plated on LB agar (Amp) plates and 
incubated at 37° C. overnight. Cells harboring pDD34-ZM-
GFP-BADH were seen to fluoresce when exposed to UV 
light, as is seen in FIG. 17B. To test the aadA gene 
expression, cells harboring pDD33-ZM-aadA-BADH plas-
mid were plated on LB agar plates containing spectinomycin 
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(100 mg/ml) and incubated at 37° C. overnight. Transformed 
cells grow on spectinomycin, as can be seen in FIG. 18B. 
FIG. 19 shows GFP expression in embryogenic maize 
cultures studied under the confocal microscope. FIG. 19A is 
a non-transgenic control, while FIG. 19B-C are transformed 
maize embryogenic calli. 
The selection in FIG. 19 was initiated two days after 
bombardment by transferring the bombarded calli to callus 
induction medium containing BA or streptomycin. After 
eight weeks, a number of the healthy growing calli from 10 
different bombardment experiments were examined for GFP 
expression under the fluorescent stereomicroscope and the 
confocal microscope. Somatic embryos were regenerated on 
maize regeneration medium containing BA or streptomycin. 
8 
The aforementioned transformation of maize and carrot 
chloroplast provides a novel approach for improved vac-
cines with the creation of an edible vaccine, which provides 
a heat stable environment, allows easy administration at 
lower cost, and stimulates the mucosa! and systemic 
immune responses. There still remain a number of hurdles 
which need to be overcome, such as the fact that protective 
antigens tend to be very large and unstable proteins (83 
kDa); such large proteins have never been expressed before 
in transgenic chloroplasts, and to date the Applicant is 
unaware of the expression and assembly of heptamers in 
transgenic chloroplasts. 
Based upon the vector construct described above and 
set-forth in further detail in this application, it is possible to 
have a general construct in edible plants where it can be 
determined through experimentation which construct can 
elicit the strongest immune response to bacterial toxin 
challenges such as, but not limiting, plague or anthrax. As an 
FIG. 20A shows maize plants on regeneration medium 15 
containing streptomycin or betaine aldehyde. FIG. 20A 
illustrates maize chloroplast transgenic plants which were 
capable of growth on the selection agent indicating that 
construction of transgenic maize, while untransfomed maize 
plants did not grow on the selection medium. 
FIG. 20B shows PCR confirmation of chloroplast trans-
genic plants using appropriate primers. Lanes 1-3, plants 
transformed with pDD34-ZM-gfp-BADH and Lanes 4-5, 
plants transformed with pDD33-ZM-aadA-BADH. Lanes -
and + represent the negative and positive controls respec- 25 
tively. Genomic DNA was isolated from the leaf tissues and 
PCR was performed on transformed and non-transformed 
tissues using appropriate primers. 
20 
example, FIG. 16 offers a schematic of a construct as an 
example of construct which could elicit an immune response 
to anthrax where, in this non-limiting example, gene X is 
chosen from; 1) LF27-PA63; 2) CTB-LF27; 3) LF27-PA63+ 
CTB-LF27; 4) LF27+PA. These antigens derived from these 
FIGS. 21A and 22A show the schematic construction of 
carrot chloroplast transformation vectors. The construction 30 
of the carrot chloroplast transformation vector illustrated in 
FIGS. 21A and 22A have flanking regions that were ampli-
fied using PCR. The PCR products were then cloned and the 
expression cassette was inserted in the transcriptionally 
active spacer region between trnI/trnA genes. The expres- 35 
sion cassette of FIG. 21A has the Prrn promoter driving the 
expression of GFP and BADH, which are regulated by (5') 
gene10/rps16 3' and psbA 5'/3' UTRs respectively. The 
expression cassette of FIG. 22A has the Prrn promoter 
driving the expression of aadA and BADH. The latter gene 40 
is regulated by (5') gene10/rps16 3' UTRs. 
Functions of the genes in the carrot chloroplast transfor-
mation vectors were tested in E. coli. For observing GFP 
expression, cells were plated on LB agar (Amp) plates and 
incubated at 37° C. overnight. Cells harboring pDD37-DC- 45 
GFP-BADH were seen to fluoresce when exposed to UV 
light (A). To test the aadA gene expression, cells harboring 
pDD36-DC-aadA-BADH plasmid were plated on LB agar 
plates containing spectinomycin (100 mg/ml) and incubated 
at 37° C. overnight. Transformed cells grow on spectino- 50 
mycin (B). 
Functions of the genes in the carrot chloroplast transfor-
mation vectors were tested in E. coli. For observing GFP 
expression, cells were plated on LB agar (Amp) plates and 
incubated at 37° C. overnight. Cells harboring pDD34-ZM- 55 
GFP-BADH were seen to fluoresce when exposed to UV 
light as is seen in FIG. 21B. To test the aadA gene expres-
sion, cells harboring pDD33-ZM-aadA-BADH plasmid 
were plated on LB agar plates containing spectinomycin 
(100 µg/ml) and incubated at 37° C. overnight. Transformed 60 
cells grow on spectinomycin, as is seen in FIG. 22B. 
FIG. 23 (A-D) shows expression of GFP in different 
stages of transgenic carrot cultures studied under confocal 
microscope (A) Untransformed control, (B) Embryogenic 
callus, (C) Embryogenic callus differentiated into globular 65 
somatic embryos and (D) Somatic embryo with differenti-
ated cotyledons. 
genes have been shown to elicit the immune response to 
anthrax. It is noted however that a number of known genes, 
which code for a bacterial antigen could be utilized in the 
construct. 
Edible vaccines are heat stable unlike conventional vac-
cines which tend to be heat sensitive. An edible vaccine has 
a longer shelf life and does not require expensive refrigera-
tion equipment. The heat sensitivity of the conventional 
vaccine makes it expensive, capricious and destination lim-
ited with a series of refrigeration steps during the transpor-
tation process from manufacture to final destination. 
Another major cause for the high cost of biopharmaceutical 
production is purification; for example, during insulin pro-
duction, chromatography accounts for 30% of the produc-
tion cost and 70% of the set up cost. Therefore, oral delivery 
of properly folded and fully functional biopharmaceuticals 
could potentially reduce production costs by 90%. In one 
study it was estimated that the banana could deliver a 
vaccine (Hepatitis B) at two cents per dose compared to 
approximately $125 per dose for conventional Hepatitis B 
vaccine injection. Bioencapsulation of pharmaceutical pro-
teins within plant cells offers protection against digestion in 
the stomach while allowing successful delivery. In three 
human clinical trials performed with plant derived vaccines, 
plant cells proved sufficient for vaccinogen protection 
against digestion, and the resulting vaccinogen induced 
systemic and mucosa! immune responses without the aid of 
adjuvants. Oral administration of PA has also been reported 
to offer protection against B. anthracis using an attenuated 
Salmonella strain expressing PA. However, in all these 
studies the limitation is the low levels of antigen expression 
which is overcome by the present invention. 
EXAMPLES 
Chloroplast Transformation 
It should be understood that the examples set forth herein 
are non-limiting examples, and the vectors can be used on a 
number of plants. The following description is capable of 
being utilized as illustration and guide work for transforma-
tion of plants to express any bacterial antigen gene. It can 
also be used to express viral antigen genes. 
US 7,354,760 B2 
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Example 1 
The pLD-JWl Vector 
FIG. 1 shows tobacco constructs and PCR confirmation of 5 
chloroplast transgene integration. FIG. lA shows the pLD-
JWl vector used for chloroplast transformation. The tmI and 
trnA genes were used as flanking sequences for homologous 
recombination. The constitutive 16s rRNA promoter (" 16s" 
in FIG. lC) was used to regulate transcription. The aadA 10 
gene conferring spectinomycin resistance was used for 
selection of transgenic shoots. The pag gene coding for 
anthrax protective antigen was regulated by the psbA pro-
moter and 5' (5UTR) and 3'UTR (T) elements. As shown in 
FIG. lB, The pLD-JW2 construct was made by adding 15 
orfl,2 from B. thuringiensis to the pLD-JWl vector. FIG. lC 
shows a scheme for PCR using the primers 3P and 3M to 
investigate chloroplast transgene integration. The 3P primer 
anneals to the native chloroplast genome and the 3M primer 
20 
anneals to the aadA gene, generating a 1.65 kb PCR product 
in chloroplast transgenic lines. FIG. lD shows the results of 
an analysis of randomly selected clones. Lane 1: Ladder; 
Lane 2: Negative control wild type tobacco plant DNA; 
Lane 3: Positive transgenic plant DNA (pLD-5'UTR/HIS/ 25 
THR/IFNa2b ); Lane 4-8: 5 different transgenic lines tested. 
The pLD-JWl vector (8.3 kb, see FIG. lA) was con-
structed to transform tobacco chloroplasts. This construct is 
based on the vector pLD the Applicant has used successfully 
in previous publications. Specifically, the construct is con- 30 
nected to the Applicants universal vectors, which are 
described in detail in PCT patent publication WO 99/10513, 
which is hereby incorporated by reference. The tmI and trnA 
genes were used as flanking sequences for homologous 
recombination to insert a pag-containing cassette into the 35 
spacer region between these two tRNA genes in the inverted 
repeat region of the chloroplast genome, as reported previ-
ously. It should be noted that it is possible to insert the pag 
containing cassette into any of a number of spacer regions 
between genes. The constitutive 16s rRNApromoter, which 40 
can be recognized by both the chloroplast encoded RNA 
polymerase and the nuclear encoded RNA polymerase, was 
used to drive transcription. Any of a number of promoters 
functional in plastids and well understood and known in the 
art can be used to help drive transcription. 45 
10 
Transgene Integration into the Chloroplast Genome by PCR 
Analysis: 
Chloroplast transgenic lines were generated by particle 
bombardment as described previously. After bombarding 
Nicotiana tabacum cv. Petit Havana tobacco leaves with the 
chloroplast vectors, the leaves were grown on selective 
medium containing 500 µg/ml spectinomycin. Three differ-
ent genetic events can produce spectinomycin-resistant 
tobacco shoots: (1) transgene integration into chloroplasts, 
(2) into the nuclear genome or (3) spontaneous mutants. 
PCR with two specific primers, 3P and 3M, allowed iden-
tification of shoots having the desired chloroplast transgene 
integration. The 3P primer annealed to the native chloroplast 
genome and the 3M primer annealed to the aadA gene (see 
FIG. lC). Nuclear transformants were eliminated because 
3P will not anneal and mutants were ruled out because 3M 
will not anneal. At least 50 shoots were obtained in the initial 
transformation, a high frequency which suggests that there 
was no inhibitory effects of PA. Among clones tested, in both 
constructs, all were chloroplast transformants. No sponta-
neous mutants or nuclear transformants were observed (see 
FIG. lD). 
Chloroplast Integration of Transgenes and Homoplasmy: 
Southern blots were done to further verify that the trans-
genes had been integrated into the chloroplast genome and 
to determine homoplasmy (containing only transformed 
chloroplast genomes) or heteroplasmy (containing both 
transformed and untransformed chloroplast genomes). Total 
plant DNA was digested with the enzyme Bg!II which 
generated a 4.4-kb fragment in wild type, 5.2-kb and 3-kb 
fragments in pLD-JWl transgenic lines, and 6.8-kb and 3-kb 
fragments in pLD-JW2 transgenic lines when hybridized 
with a 0.81-kb probe made from chloroplast flanking 
sequences (see FIG. 2A-D). The blots were also hybridized 
with a 0.52-kb probe made from pag coding sequence (see 
FIG. 2E). All of the pLD-JW2 plants appeared to be 
homoplasmic. In the pLD-JWl plants, transgenic line 2 
appeared to be heteroplasmic, which is not uncommon to 
find in Ta plants. Ta refers to first generation transgenic lines 
and T 1 refers to second generation lines obtained by germi-
nation of seeds from Ta. 
FIG. 2 shows southern blots to investigate the site of 
transgene integration and determine homoplasmy or hetero-
plasmy. The figure shows a schematic diagram of the 
expected products from digestion of wild type untrans-
formed plant as follows: FIG. 2A shows plants transformed 
with pLD-JWl; FIG. 2B shows plants transformed with 
pLD-JW2. FIG. 2D shows a flanking sequence probe reveal-
The aadA gene conferring spectinomycin resistance was 
used for selection of transgenic shoots. It is noted however, 
that the use other antibiotic-resistant genes or an antibiotic 
free selectable marker such as BADH, could also be used in 
the construction of the vector. The pag gene coding for 
anthrax protective antigen was regulated by the psbA 5' and 
3' elements. The 5'UTR from psbA, including its promoter, 
was used for transcription and translation enhancement and 
the 3'UTR region conferred transcript stability. 
50 ing heteroplasmy in pLD-JWl line and homoplasmy in 
pLD-JW2 lines. FIG. 2E shows pag sequence probe showing 
presence of pag in transgenic lines. 
One skilled in the art would recognize that an alternative 
chloroplast vector can be constructed without the use of any 
promoter, because all polycistronic spacer regions contain a 
native promoter which can be used to drive transcription. 
A second construct was made by adding orfl,2 from B. 
thuringiensis to the pLD-JWl vector, forming the pLD-JW2 
vector (see FIG. lB). The orfl,2 gene codes for a putative 
chaperone. Including the orfl,2 gene was done to test 
whether the putative chaperone could fold a heterologous 
Bacillus protein (i.e., PA) into cuboidal crystals or form 
inclusion bodies, protect PA from proteolytic degradation, 
and thereby facilitate purification. 
PA Expression in Transgenic Chloroplasts: 
Western blots were performed on transgenic lines con-
55 taining the two different constructs. Full length 83-kDa 
polypeptide was detected on blots, confirming PA expression 
in transgenic lines and absence of unique proteases that 
cleave PA in plant cells (see FIGS. 3A-C). Presence of active 
furin or trypsin-like proteases would have resulted in a 
60 63-kDa protein due to cleavage at the sequence RKKR (SEQ 
ID NO:l) (amino acids 164-167). The sequence FFD (SEQ 
ID N0:2) at residues 312-314 is another site that is highly 
sensitive to chymottypsin-like enzymes, and cleavage would 
have resulted in 47- and 37-kDa fragments. No other cleaved 
65 PA products were observed (see full length blots shown), 
demonstrating stability of chloroplast derived PA. Prior to 
the Applicant's discovery, it was widely believed that pro-
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teases would cleave long antigenic bacterial peptides, but 
this invention illustrates that the antigenic bacterial peptides 
are free from protolytic degradation. 
The T 1 transgenic lines showed a greater amount of PA in 
the pLD-JWl lines as compared to the pLD-JW2 lines. 
Additional western blots were done comparing two different 
detergents in the extraction buffers, CHAPS and SDS, and 
both were found to extract PA equally well (see FIG. 3C). 
The supernatant and the homogenate were also found to be 
comparable suggesting that most of the PA is in the soluble 
fraction. After storage for two days at 4 ° C. and -20° C., the 
PA in plant crude extracts is quite stable (see FIG. 3C). 
Powdered leaf was stored at -80° C. for several months 
before performing western blots or functional assays; this 
did not result in any noticeable decrease in PA quantity or 
functionality. This facilitates long term storage of harvested 
leaves before extraction of PA for vaccine production. 
Native PA has been shown to be highly unstable due to 
proteolysis-sensitive sites, which have been modified to 
confer better stability. 
Quantification of PA in Transgenic Chloroplasts: 
In order to quantify the amount of PA in transgenic 
chloroplasts, western blots were used to observe varying 
dilutions of the crude extract. PA was quantified using gel 
documentation software (Bio-Rad). Based on western blot 
analysis, pLD-JWl T 1 transgenic lines showed 44 µg PA/g 
of fresh tissue (22 µg/ml). An average tobacco leaf weighed 
6.5 g; therefore 286 µg PA could be expressed per leaf. The 
pLD-JW2 transgenic lines showed lower levels of PA accu-
mulation, probably due to interference of both UTRs, result-
ing in decrease in translation. We have observed recently 
that the combination ofORF-psbA5'UTR decreases expres-
sion of human serum albumin in transgenic chloroplasts. 
The psbA regulatory sequences, including the promoters 
and UTRs, have been shown to enhance translation and 
accumulation of foreign proteins under continuous light. 
Therefore, pLD-JWl T 1 transgenic plants were placed in 
continuous light and young, mature, and old leaves were 
collected after 3 or 5 days of continuous illumination. 
Western blots were performed using different dilutions of 
crude plant extracts (see FIG. 4A-B). The 3 day mature and 
young leaves contained 80 µg PA or 108 µg PA/g of fresh 
tissue. The 5 day old, mature and young leaves contained 32 
µg PA, 108 µg PA or 156 µg PA/g of fresh tissue, respec-
tively. Thus, young leaves showed the highest accumulation 
12 
PA accumulation was visualized in crude plant extracts by 
Coomassie staining. When a capture ELISA was used to 
quantify PA, it appeared that PA constituted a large percent-
age of total soluble protein in some extracts. While these 
5 values may reflect detection of partially cleaved PA, they do 
not result from non-specific interaction of the antibodies 
with any other proteins, because no signal was detected in 
untransformed plants. However, the data set forth herein is 
from quantitative scanning of polyacrylamide gels and not 
10 from the capture ELISA. 
PA Functionality Determined by Macrophage Lysis: 
Supernatant and homogenate samples from both T0 con-
structs, pLD-JWl and pLD-JW2, were tested. Two different 
15 buffers were used to extract proteins--one contained 
CHAPS detergent and one did not have any detergent. The 
PA produced in chloroplast transgenic lines was able to bind 
to the anthrax toxin receptor, be cleaved to the 63-kDa 
fragment, heptamerize, bind LF, be internalized and lyse the 
20 macrophage cells. Therefore the transgenic plants were 
shown to produce fully functional PA (see FIG. SA). Active 
PA was found in both the supernatant and homogenate 
fractions; but was quantitated only in the former. The assay 
using CHAPS gave a result of the pLD-JWl supernatant 
25 with the best yield. In the absence of any detergent, the 
supernatants lysed the macrophage cells better than the 
homogenates. Crude plant extracts contained up to 5 µg per 
ml functional PA confirming expression of high levels of 
functional PA. Supernatant samples from Tl pLD-JWl 
30 transgenic lines were tested and they resulted in approxi-
mately 12-25 µg functional PA per ml (see FIG. SB) and the 
toxicity was entirely dependent on the presence of LF. 
The threat of biological warfare and terrorism is real. The 
most effective way to prevent or deter effective use of 
35 anthrax as a weapon would be to produce an efficacious and 
inexpensive vaccine. Plants are an inexpensive and easy way 
to produce recombinant proteins, without human or animal 
pathogen contamination. Because one acre of tobacco yields 
up to 40 tons of fresh leaves (40,000 kg in three cuttings), 
40 the production could be up to 6.24 kg PA per acre based on 
expression levels reported in this manuscript. There is less 
than 50% loss during purification from plant extracts (loss of 
foreign protein is generally between 30 and 90% ), and at 5 
µg PA per dose (which is roughly equivalent to prior art 
45 vaccine which is in a range of 1.75 to 7 µg PA), one can 
produce 600 million doses of vaccine per acre of tobacco. 
Thus a few acres of transgenic tobacco can meet the world's 
need for the anthrax vaccine. of PA and old leaves showed the lowest, probably due to 
proteolytic degradation induced during senescence. These 
assays quantified only full length PA. In spite of loading 50 
500-1000 fold more protein of untransformed plant extracts, 
Experiment Protocol for Example 1 
no cross-reacting protein was observed with the monoclonal 
antibody used. 
Bombardment and Selection of Transgenic Plants: 
Sterile Nicotiana tabacum cv. Petit Havana tobacco 
leaves were bombarded using the Bio-Rad PDS-1000/He FIG. 4 shows total protein from plant extracts loaded in 
each lane is shown in parenthesis. FIG. 4A shows pLD-JWl 
transgenic line in 3 days of continuous light, 1 :20 dilutions. 
Lane 1: old leaf (187 ng); Lane 2: mature leaf (369 ng); Lane 
55 biolistic device as previously described. The bombarded 
leaves were placed on RMOP medium containing 500 µg/ml 
spectinomycin for two rounds of selection on plates and 
subsequently moved to jars ofMSO medium containing 500 3: young leaf (594 ng); Lanes 4-5: blank; Lane 6: 10 ng PA; 
Lane 7: 20 ng PA; Lane 9: ladder; Lane 10: wild type 
(15,000 ng). FIG. 4B shows pLD-JWl transgenic line in 5 60 
days of continuous light, 1 :20 dilutions. Lane 1: old leaf 
(214 ng); Lane 2: mature leaf (588 ng); Lane 3: young leaf 
(745 ng); Lane 6: 10 ng PA; Lane 7: 20 ng PA; Lane 8: blank; 
Lane 9: ladder; Lane 10: wild type (15,000 ng). FIG. 4C is 
a histogram ofµg PA/g fresh tissue in young, mature, and old 65 
leaves after 3 (blue) and 5 (red) days of continuous illumi-
nation. 
µg/ml spectinomycin. 
PCR Analysis to Test Stable Integration: 
DNA was extracted from tobacco leaves using Qiagen 
DNeasy Plant Mini Kit available from Qiagen, Valencia, 
Calif. PCR was performed using the Perkin Elmer Gene 
Amp PCR System 2400 (available from Perkin Elmer, 
Chicago, Ill.). PCR reactions contained template DNA, 
lxTaq buffer, 0.5 mM dNTPs, 0.2 mM 3P primer, 0.2 mM 
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3M primer, 0.05 units/µ! Taq Polymerase, and 0.5 mM 
MgCl2 . Samples were run for 30 cycles as follows: 95° C. 
for 1 min, 65° C. for 1 min, and 72° C. for 2 min with a 5 
min ramp up at 95° C. and a 72° C. hold for 10 min after 
cycles complete. PCR products were separated on 1 % aga- 5 
rose gels. 
Southern Blot Analysis: 
14 
Macrophage Lysis Assays: 
Approximately 100 mg of powdered leaf tissue was 
extracted with 200 µI of extraction buffer. For the superna-
tant fraction, the buffer and tissue were centrifuged for 5 
minutes at 10,000xg and the supernatant was placed in a 
new tube. For the homogenate, it was all of the tissue and the 
buffer. RAW 264.7 macrophage cells were plated in 96-well 
plates in 120 µI DMEM medium and grown to 50% con-
fluence. The medium was aspirated and replaced with 100 µI Total plant DNA was digested with Bg!II and run on a 
0.8% agarose gel at 50 V for 2 hours. The gel was soaked in 
0.25 N HCI for 15 minutes and then rinsed 2x with water. 
The gel was soaked in transfer buffer (0.4 N NaOH, 1 M 
NaCl) for 20 minutes and then transferred overnight to a 
nitrocellulose membrane. The membrane was rinsed twice 
10 medium containing 250 ng/ml LF. The control plate received 
medium with no LF to test toxicity of plant material and 
buffers. In separate 96-well plates, the plant samples were 
diluted serially 2-fold and 40 µI of the dilutions were 
transferred onto the RAW cells so the top row had plant 
15 extract at 1:14 dilution. MTT (3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide) was added after 5-10 
hours to assess cell death. Gu, M. L., Leppla, S. H., 
Klinman, D. M. Protection against anthrax toxin by vacci-
nation with a DNA plasmid encoding anthrax protective 
in 2xSSC (0.3 M NaCl, 0.03 M Sodium citrate), dried on 
filter paper, and then crosslinked in the GS GeneLinker 
(Stratagene, La Jolla, Calif.). The flanking sequence probe 
was made by digesting pUC-CT vector DNA with BamHI 
and Bg!II to generate a 0.81 kb probe. Lee, S. B., Byun, M. 
0., Daniell, H. Accumulation oftrehalose within transgenic 
chloroplasts confers drought tolerance. Molecular Breeding 
(in press) (2002). The pag probe was made by digesting pag 
with Neal to generate a 0.52 kb probe. The probes were 
labeled with 32P using the ProbeQuant G-50 Micro Colunms 25 
(Amersham, Arlington Heights, Ill.). The probes were 
hybridized with the membranes using Stratagene QUICK-
HYB hybridization solution and protocol (Stratagene, La 
Jolla, Calif.). 
Western Blot Analysis: 
Approximately 100 mg ofleaftissue was ground in liquid 
nitrogen with a mortar and pestle and stored at -80° C. for 
several months. When it was time to extract the proteins, the 
powder was removed from -80° C. and 200 µI of plant 
extraction buffer was added and mixed with mechanical 
pestle (0.1% SDS, lOOmMNaCI, 200mMTris-HC!pH 8.0, 
0.05% Tween 20, 400 mM sucrose, 2 mM PMSF). The plant 
extract was then centrifuged for 5 minutes at 1 O,OOOxg to 
pellet the plant material. The supernatant containing the 
extracted protein was transferred to a fresh tube and an 
aliquot was taken out, combined with sample loading buffer, 
boiled, and then run on 8% SDS-PAGE gels for one hour at 
80 V, then 2 hours at 150 V. Gels were transferred overnight 
at 10 V to nitrocellulose membrane. The membrane was 
blocked with PTM (lxPBS, 0.05% Tween 20, and 3% dry 
milk). PA was detected with anti-PA monoclonal antibody 
14B7. Secondary antibody used was goat anti-mouse IgG 
conjugated to horseradish peroxidase (American Qualex 
Antibodies, Al 06PN). 
20 antigen (Vaccine. 17, 340-344 (1999)). 
Example 2 
Transformation of the Tomato Chloroplast Genome 
Prior to the creation of the pTom-BADH2-G10-pag -8.8 
kb vector construct (FIG. 7), the Applicant constructed the 
pLD Tom-BADH vector (FIG. 6A) illustrating the ability to 
transform the chloroplast genome of edible dicots. The 
30 Tom-BADH vector was constructed to with two selectable 
marker genes (BA and spectinomycin) to test ability of 
transformed plants to grow on BA as compared to specti-
nomycin. The pLD-Tom-BADH vector contains the chi-
meric aadA gene and the BADH gene driven by the consti-
35 tutive 16 S rRNA promoter and regulated by the 3'UTR 
region of psbA gene from petunia plastid genome. In this 
construct both, aadA and BADH possess the chloroplast 
preferred ribosomal binding site, GGAGG. Another suitable 
vector used for tomato chloroplast transformation is the 
40 pLD-Tom-UTR-BADH vector, which has the constitutive 
16 S rRNA promoter driving the expression of the dicistron, 
in which the BADH is under the regulation of the promoter 
and the 5'UTR of the psbA gene and the 3'UTR of psbA 
gene, for enhanced expression. FIG. 6B shows the PCR of 
45 tomato chloroplast transformed with the pLD-Tom-BADH 
using 3P/3M primers. Specifically FIG. 6B shows, Lane 1 
and 9-1 Kb plus Ladder; 2-mutant; 3-Clone#8; 
4--Clone#9; 5-Clone#ll; 6-Wild type; 7-Positive con-
trol; 8-pLD-Tom-BADH. From results observed in the gel 
50 in FIG. 6B, integration of transgene is quite evident. 
FIGS. llAand B show the response of tomato cotyledons 
transformed with the pLD-Tom-BADH vector grown on 
RMOP, which is supplemented with 2.5 nm betaine alde-
hyde, wherein llA shows the wild type control and llB 
55 shows the transformant. 
The stability assay utilized SDS buffer (0.1 % SDS, 100 
mM NaCl, 10 mM EDTA, 200 mM Tris-HCI pH 8.0, 0.05% 
Tween 20, 14 mM ~-mercaptoethanol, 400 mM sucrose, 2 
mM PMSF) and CHAPS buffer (4% CHAPS, 100 mM 
NaCl, 10 mM EDTA, 200 mM Tris-HCI pH 8.0, 14 mM 
~-mercaptoethanol, 400 mM sucrose, 2 mM PMSF). Two 
hundred µI of each buffer was added to 100 mg powdered 
leaf tissue. For supernatant fractions, the extraction was 
centrifuged at 10,000xg for 5 minutes and supernatant was 
removed. For homogenate, the entire extract was used. The 60 
samples were stored at 4 ° C. and -20° C. for two days. The 
rest of the western protocol was the same as described 
above. Dilutions of 1: 10 and 1 :20 of the protein extracts 
were made and run on the gel along with 20, 10, and 5 ng 
After successful construction and integration into the 
tomato chloroplast genome using the pLD Tom-BADH 
vector of FIG. 6A, the Applicant then constructed the 
pTom-BADH2-G10-pag -8.8 kb vector, which is illustrated 
in FIG. 7. FIG. 7 shows the schematic construct of the 
pTom-BADH2-G10-pag -8.8 kb vector, which was con-
structed containing the selectable marker gene BADH. This 
construct is also be made using the aad gene to confer 
spectinomycin resistance in place of the BADH gene. After 
bombarding the tomato cotyledons (seed leaves or embry-
onic leaves) with the tomato construct of FIG. 7, the 
cotyledons were put on selection media containing Betaine 
of PA protein standards to generate a standard curve for 65 
protein quantification. After the film was developed, the PA 
was quantified using the Gel-Doc. 
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Aldeyhyde (BA) and calli formed. The calli were transferred 
to new selection media to obtain shoots. 
FIG. 10 shows the first selection after bombardment with 
the pTom-BADH2-G10-pag -8.8 kb vector, wherein the 
cotyledons were incubated in the dark for 48 hours and then 
the bombarded cotyledons were cut. The RMOP medium 
shown in FIG. 10 is a shoot inducing media. The bombarded 
cotyledons were grown on 2.5 mM Betaine Aldehyde (BA) 
for selection. 
FIG. 8 shows the PCR test that was performed to deter- 10 
mine integration of the pTom-BADH2-G10-pag -8.8 kb 
vector, where the tomato shoots were tested with PCR to 
confirm integration of the transgene. In FIG. 8, the + is 
pTOM-GlO-PA vector control, - is WT Tomato plant, and 
#3 is the transgenic tomato plant. This confirmation utilized 15 
appropriate primers. 
To apply the plastid transformation technology to edible 
plants to produce an edible vaccine, a first generation tomato 
vector is constructed containing pag. TrnI and trnA are 
homologous recombination regions in tomato; 5'UTR from 
20 psbA is used for translation enhancement and also contains 
it's own promoter; BADH gene confers Betaine Aldehyde 
(BA) resistance; GlO is a translation enhancer from the T7 
bacteriophage; pag codes for the protective antigen, and T is 
the psbA terminator. 
16 
neutralization by serum antibodies following intranasal 
immunization. Equivalent results were seen following tran-
scutaneous immunization. 
Tomato Chloroplast Integration Vector: 
Since the expression of the foreign protein is desired in 
chromoplasts of tomato fruit, the gene of interest needs to be 
under the control of a regulatory sequence that is free from 
cellular control. In this context, examples of suitable can-
didate regulatory sequences are the T7 gene 10 leader 
sequence and cry2Aa2 UTR. The T7 gene 10 leader 
sequence is used to express foreign proteins in transgenic 
chromoplasts. The cry2Aa2 UTR accumulates foreign pro-
tein in chromoplasts as efficiently as the psbA UTR. The 
selectable marker for the future generation vectors can 
optionally be the BADH gene under the regulation of psbA 
promoter and 5'UTR as psbA is one of the most efficiently 
translated chloroplast genes in green tissues. Since green 
tissue is used for introducing the transgene into the chloro-
plasts in tomato, it is ideal to use the light regulated psbA 
UTR for the selectable marker. 
Tomato Seed Sterilization and Growth Conditions: 
FIG. 9 shows tomato seeds (Moneymaker and Ady vari-
eties) that are surface sterilized with ethanol for 30 s, 
followed by a 20 min treatment with 1.5% NaOCI and 0.1 % 
The pDDll vector is cleaved with NdeI & Natl to remove 
the gene and leave opened pB!ue-G 10 region of the vector. 
The pB!ue-T7-pag vector is then cleaved with NdeI & Natl 
to remove the pag gene -2.2 kb. The pag gene is ligated into 
the opened pB!ue-G 10 vector, and the resulting pB!ue-G 10-
pag is cleaved with SmaI & Natl to remove the GlO-pag 
-5.2 kb segment from the pB!ue-G 10-pag vector. Finally the 
pTom-BADH2 vector is cleaved with SmaI and Natl, and 
then the G 10-pag fragment is ligated into the vector creating 
25 Tween 20. Seeds are washed thoroughly with sterile water 
(at least 3-4 times) and transferred to germination media 
(FIG. 14). Germination media consists of MS salts with 30% 
sucrose and 0.8% agar. About 20 seeds are inoculated per 
bottle and placed under a photoperiod of 16 h light and 8 h 
30 dark for 8-10 days to obtain cotyledons for particle bom-
bardment. The cotyledons are then excised either as an 
explant for bombardment or the resulting seedlings are used 
for transplantation to obtain leaves. 
The cotyledons and leaf material are bombarded using the a pTOM-BADH2-G10-pag -8.8 kb (FIG. 7). 
PCR Confirmation of Transgene Integration: 
After bombarding the tomato cotyledons (seed leaves or 
embryonic leaves) with the tomato construct vector, pTOM-
BADH2-G 10-pag -8.8 kb, the cotyledons are put on selec-
tion media containing Betaine Aldeyhyde (BA) and calli 
formed (FIG. 10). The calli are transferred to new selection 
media to obtain shoots. Shoots are tested with PCR to 
35 particle gun. After bombardment the explants are then 
incubated in the dark for 48 h. The cotyledons and leaves are 
then cut into small pieces and placed onto RMOP media 
supplemented with 2.5, 5.0 and 7.5 mM ofbetaine aldehyde 
for regeneration. In the case of cotyledons, the concentration 
of 2.5 nm BA is optimal, but not required, as regeneration of 
40 putative transformants could be observed after two weeks. 
confirm integration of the transgene, which utilizes appro-
priate primers (FIG. 8). 
Mucosa! 
Anthrax: 
and Transcutaneous Immunization Against 45 
Specifically, there is no response on media having higher 
concentrations of 5.0 and 7.5 mM BA. With leaves, the 
concentration of 1 and 1.5 mM is optimal for pLD-Tom-
BADH and pLD-Tom-UTR-BADH respectively. 
Preparation and Analysis of Stable Tomato Plant Transfor-
mants: 
Selection is optimally performed in the presence of BA, 
but has also been performed in the presence of antibiotics. 
50 After selection, PCR analysis is performed as described 
above, as is well understood in the art. Finally Southern and 
northern blot analyses are performed as described above, 
and well understood in the art, to determine the amount and 
level of transformation in the chloroplast genome. 
Anthrax vaccine studies focused on mucosa! and trans-
cutaneous immunization with rPA as a vaccine antigen when 
delivered in conjunction with a novel adjuvant, designated 
LT(R192G). This adjuvant was shown to be effective at 
augmenting protection against a variety of bacterial, viral, 
and fungal pathogens when delivered with appropriate anti-
gens intranasally, orally, rectally, or transcutaneously. This 
adjuvant was developed by the Clements laboratory at 
Tulane University Health Sciences Center with funding 55 
from NIH and the Department of Defense and has been 
evaluated in a number of Phase I and Phase II clinical trials. 
In rPA studies, a number of immunologic outcomes were 
measured, but the studies focused primarily on those asso-
ciated with protection against inhaled pathogens-serum 
and bronchial lavage (BAL) fluid antibodies. It was dem- 60 
onstrated that mucosa! and transcutaneous immunization of 
mice with rPA induces high levels of antigen-specific anti-
bodies in serum and in bronchoalveolar lavage fluids. More-
over, circulating anti-rPA antibodies are able to neutralize 
the cytotoxic effect of anthrax Lethal Toxin when tested in 65 
macrophage cytotoxicity assays. FIG. 12 shows the serum 
anti-PA as determined by ELISA and the in vitro toxin 
Example 3 
Transformation of Carrot to Produce Anthrax 
Vaccine 
Carrot (Daucus carota L.) is a biennial plant grown for its 
edible taproot. It is one of the most important vegetables 
used worldwide for human consumption. Carrot taproots are 
rich in vitamin A and fiber and are ideal to genetically 
manipulate in the chromoplast for the production of edible 
vaccines. For transformation of carrot, flanking sequences 
(trnI and tmA) are amplified with the help of PCR. Duration 
for regeneration of carrot plantlets is shortened to four 
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months from eight months when replacing the antibiotic 
selection with BA. The same chloroplast constructs as 
described above for tomatoes are used for carrot except that 
homologous recombination regions i.e. tml and trnA are 
derived from carrot chloroplast DNA. The advantage of 5 
using carrot is that from small clusters of cells or a small 
piece of carrot one can get thousands of transgenic plants in 
a limited space. Moreover, single cells are directly in contact 
with the culture media surface. Therefore, even a small 
quantity of selecting agent (betaine aldehyde) is more effec-
10 
tive in comparison to other larger tissues. Carrot is easy to 
store for long periods of time. 
Plant Material and Tissue Culture: 
18 
from Fl gene (513 bp/15.5 kDa) and the entire V antigen 
(980 bp/35 kDa). The entire immunogenic sequence will be 
( 441 +980 +6 for a hinge= 143 7 bp ). With the protein of 4 78 
amino acids having a calculated mass of 53,193 and a pl of 
5.1 has shown this fusion protein to be immunoprotective. 
Fl-V was modified to add an EcoRl site. This fragment 
is cloned into the universal chloroplast vector, which has 
been described above, with the psbA 5'UTR upstream of the 
Fl-V fusion. The use of the psbA 5'UTR, is not required, but 
it has been shown to increase expression of foreign proteins 
by chloroplast. 
Large-scale expression of the fusion protein results in the 
formation of inclusion bodies as observed with several other 
Seeds of carrot (Daucus carota L. cv Nantaise) are sown 
in pots and placed under a growth chamber with appropriate 
growth conditions for as little as four weeks to as long as a 
year. The hypocotyls are then cut into segments of 1 cm long 
and placed either on semi-solid callus induction medium or 
foreign proteins expressed in transgenic chloroplasts. These 
15 inclusion bodies are easily separated by centrifugation. 
in 50 ml MS medium containing 3% sucrose, 0.1 mg/I 
2,4-dichlorophenoxyacetic acid (2,4-D) having pH 5.7. 
After 3 weeks of continuous shaking at 24 ° C. and 120 rpm, 
liberated cells are collected on a 100 µM mesh, centrifuged 
(150xg for lo min) and resuspended in fresh medium. 
Rapidly growing cell cultures can be subcultured weekly. 
Next, callus formation from hypocotyls segments is estab-
lished on semi-solid MS medium (Carolina Biological sup-
ply company) containing 1 mg/I kinetin and 3 mg/I 2,4-D. 
Homogenously growing calli is subcultured every 4 weeks 
on fresh medium. The resulting friable calli is then resus-
pended in 50 ml MS medium containing 3% sucrose and 0.1 
mg/kinetin. Finally, suspension-cultured cells are filtered 
through a 100 µM mesh and subjected to bombardment with 
chloroplast vectors. 
Another option is use of ammonium sulphate for the pre-
cipitation of the protein. 
Optionally, a His-tag with an enterokinase cut site was 
added to the above construct. The His-tag allows for puri-
20 fication on a nickel colunm with subsequent cleavage of the 
fusion protein from the His-tag. 
The plasmid pPW731 (a pET-24 vector) carrying the gene 
for the F 1 V fusion protein was delivered in BLR strain of E. 
coli. Because of the exonuclease activity in BLR, XLl-Blue 
25 strain of E.coli was transformed with pPW731. Using Ndel 
and Natl, FlV was cut out of pPW731 and ligated into 
PCR2.1 with 5' psbA. In order to ligate 5' psbA-Fl V into the 
universal chloroplast vector, pLD-CtV, PCR2.l-5' psbA-
FlV was cut with Sad, and blunt ended, then cut with Natl. 
30 This was ligated into pLD-CtV which had been cut with 
EcoRV (blunt end) and Natl. This produced the chloroplast 
vector pLDS-FlV containing the 5'UTR psbA upstream of 
FlV, which was then used for bombardment. The use of the 
Bombardment and Regeneration of Carrot Chromoplast 35 
Transgenic Plants: 
psbA 5'UTR has proven to increase expression of foreign 
proteins by chloroplasts. 
FIG. 13A shows the construct of the pLDS-Fl V vector, 
wherein the vector contains the FIN antigen gene contained 
in the spacer region between the tml and tmA genes. It 
should be understood that the FIN antigen gene could be 
40 inserted into any of a number of spacer regions between 
chloroplast genes, which are described and illustrated in 
Sugita, M. Sugiura, M. Regulation of gene expression in 
chloroplast of higher plants, Plant Molecular Biology 
Fine cell suspension culture of carrot, evenly spread over 
MS semi-solid medium is used for bomardment. After 
bombardment the explants are incubated in the dark for 48 
hand later in appropriate light condition (16/8 h day/night 
cycle at 24° C.). Somatic embryogenesis is induced in a 
suspension of single cells and small clusters harvested on 
sieve and low-speed centrifugation. The harvested cells are 
washed once with hormone free liquid MS medium and 
resuspended in 40 ml hormone free MS medium containing 45 
different concentrations ofbetaine aldehyde (1.5, 2.5 and 3.5 
mM). Transgenic somatic embryos, visible 2 weeks after 
induction, are selected manually and transferred onto plates 
with semi-solid MS medium containing 1.5% sucrose and 
variable concentrations ofbetaine aldehyde (1.5, 2.5 and 3.5 
mM). The plates are sealed with parafilm. After two weeks, 
somatic embryos development into plantlets which are trans-
ferred to soil in pots. Initially, the pots are covered with 
plastic bags to maintain high humidity and irrigated with 
progressively reduced concentrations of MS salts for the first 
week, followed by tap water in the second week. Transgenic 
plants with stable expression of recombinant protein are then 
utilized for suitable assays. 
Example 4 
Construction for the Fl V Fusion Protein (the 
Plague Antigen) 
32:315-326, 1996). 
FIG. 13B shows PCR restriction enzyme analysis of 
pLDS-FlV withXhoI, EcoRI, and Ndel, which showed that 
the psbA-FlV sequence to be in proper orientation in pLD. 
(Xhol yielding: 340 bp, 2679 bp, and 4634 bp: EcoRI 
yielding 682 bp, and 6953 bp: and XhoI/NdeI yielding 340 
50 bp, 925 bp, 1102 bp, 1620 bp, 3610 bp, and incomplete 
digestion at 2601 bp, and 4550 bp ). Lane 1: 1 KB Ladder, 
Lane 2: pLDS 37C, Lane 3: pLDS 4C, Lane 4: EcoRI, Lane 
5: Xhol, Lane 6: XhoI/NdeI (overnight), Lane 7: XhoI/NdeI. 
The sequencing of pLDS-(5' psbA)-FlV using the 5'UTR 
55 primer, which lands on the 5' psbA, showed no changes 
during vector construction. 
FIGS. 14A and 14B show PCR confirmation oftransgene 
integration into the chloroplast genome. 
After bombarding tobacco leaves with pLDS-FlV, there 
60 are three possibilities that might produce shoots: chloroplast 
transgenic, nuclear transgenic, and mutants resistant to spec-
tinomycin. In order to select chloroplast transgenic plants 
we utilize two PCR reactions. The first (FIG. 14A), which 
The production of Yersinia pestis vaccine in a low nico- 65 
tine strain of tobacco (LAMD) is accomplished by express-
ing in chloroplasts the F 1-V antigen fusion protein produced 
checks for chloroplast intergration, uses 3P and 3M primers 
which land on the native chloroplast geneome and the aadA 
gene, respectively. Nuclear transformants are screened out 
because 3P will not anneal. Mutants are screened out 
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because 3M will not anneal. Positive chloroplast transfor-
mants produce a 1.65 Kb PCR product. 
The second PCR reaction (FIG. 14B) uses SP which lands 
on the aadA gene and 2M which lands on trnA. This 
produces a PCR product of 1.65 kb+Insert (psbA=203 
bp+Fl V=l437 bp )=3.29 Kb. Plants 2-5, 8, and 10 clearly 
contain the transgene. 
FIG. 15A shows the western blot of pLDS-FlV from 
XLl-Blue strain of E. coli, and 15B shows the western blot 
of plants 1 and 2. 
Turning to FIG. 15A showing the Western blot of FlV 
expression in E. coli, the expression in E.coli was detected 
by rabbit anti-Fl as the primary antibody and alkaline 
phosphatase labeled goat anti-rabbit IgG as the Western blot 
10 
20 
proteins. Spontaneously forming CTB pentamers exhibit 
intact transcytosis to the external basolateral membrane of 
intestinal epithelium, and have been widely used as oral 
vaccine vehicles. 
Example 6 
Double Barrel Plastid Vectors 
Chloroplast transformation has been accomplished only 
in a few Solanaceous crops so far. There are several chal-
lenges in extending this technology to other crops. So far, 
only green chloroplasts have been transformed in which the 
leaf has been used as the explant. However, for many crops, 
including monocots, cultured non-green cells or other non-
green plant parts are used as explants. These non-green 
tissues contain proplastids instead of chloroplasts, in which 
gene expression and gene regulation systems are quite 
different. During transformation, transformed proplastids 
of Fl V expression in E. coli was detected by rabbit anti-Fl 15 
as the primary antibody and alkaline phosphatase labeled 
goat anti-rabbit IgG as the secondary antibody. Specifically 
the western blot in FIG. 15A shows: Lane 1: pLDS-FlV; 
Lane 2: Flantigen; Lane 3: V antigen; Lane 4: FlV fusion 
protein. 20 should develop into mature chloroplasts and transformed 
cells should survive the selection process during all stages of 
development. Therefore, the major challenge is to provide 
chloroplasts the ability to survive selection in the light and 
the dark, at different developmental stages. This is abso-
FIG. 15B illustrates the Western blot of Fl V expression in 
plants as was detected by rabbit anti-Fl and anti-V as 
primary antibodies and alkaline phosphatase labeled goat 
anti-rabbit IgG as the secondary antibody. Controls and 
samples were boiled. Specifically the western blot in FIG. 
15B shows: Lane 1: purified FlV fusion protein; Lane 2: 
Untransformed Petit Havana; Lane 3: Transformed plant line 
#1; Lane 4: Transformed plant line #2. From this western 
blot it is clear that transbgenic line 2 has surpassed line 1 in 
growth and is very healthy confirming that the foreign 
protein is not toxic to plants. 
Cloning Fl-V Antigen into Tomato: 
25 lutely critical because only one or two chloroplasts are 
transformed in a plant cell and these plastids should have the 
ability to survive the selection pressure, multiply and estab-
lish themselves while all other untransformed plastids are 
eliminated in the selection process. The Double Barrel 
30 Plastid Vectors accomplish this by using genes coding for 
two different enzymes capable of detoxifying the same 
selectable marker (or spectrum of selectable markers), 
driven by regulatory signals that are functional in proplastids 
The Fl-V antigen, which is a bacterial antigen, was 
cloned into the tomato pLD vector between gene 10 and rps 35 
16 terminator. This was discussed further above. In this case, 
the selectable marker, BADH, with psbA 5'UTR and psbA 3' 
follows the rpsl6 region. The second vector made contains 
Fl-V attached to the carboxy terminus ofCTB. CTB serves 
as well as in mature chloroplasts. 
The plastid vector described here is one among several 
such examples (non-limiting example). The chloroplast 
flanking sequence contains appropriate coding sequences 
and a spacer region into which the transgene cassette is 
inserted. Any spacer sequence within the plastid genome 
as a mucosa! carrier for this plague protein. 
Example 5 
Oral Delivery of Recombinant Proteins via Cholera 
Toxin B Subunit (CTB) 
The increased production of an efficient transmucosal 
carrier molecule and delivery system in chloroplasts of 
plants allows the production of plant based oral vaccines and 
fusion proteins with CTB. CTB has previously been 
expressed in nuclear transgenic plants at levels of 0.01 
(leaves) to 0.3% (tubers) of the total soluble protein. To 
increase expression levels, the chloroplast genome was 
engineered to express the CTB gene. We observed expres-
sion of oligomeric CTB at levels of 4-5% of total soluble 
plant protein. PCR and Southern Blot analyses confirmed 
stable integration of the CTB gene into the chloroplast 
genome. Western blot analysis showed that transgenic chlo-
roplast expressed CTB was antigenically identical to com-
mercially available purified CTB antigen. Also, GMl-gan-
glioside binding assays confirm that chloroplast synthesized 
CTB binds to the intestinal membrane receptor of cholera 
toxin Transgenic tobacco plants were morphologically indis-
tinguishable from untransformed plants and the introduced 
gene was found to be stably inherited in the subsequent 
generation as confirmed by PCR and Southern blot analyses. 
Thus chloroplasts form disulfide bridges to assemble foreign 
40 could be targeted for transgene integration, including tran-
scribed and transcriptionally silent spacer regions. Both 
aphA-6 and aphA-2 (nptII) genes code for enzymes that 
belong to the aminoglycoside phosphotransferase family but 
they originate from different prokaryotic organisms. 
45 Because of prokaryotic nature of the chloroplast genome, 
these genes are ideal for use in transgenic chloroplasts 
without any codon optimization. Genes of prokaryotic origin 
have been expressed at very high levels in transgenic 
chloroplasts (up to 47% of total soluble protein, DeCosa et 
50 al., 2001). Both enzymes have similar catalytic activity but 
the aphA-6 gene product has an extended ability to detoxify 
kanamycin and provides a wider spectrum of aminoglyco-
side detoxification, including amikacin. The advantage of 
choosing kanamycin as a selectable marker is that it has no 
55 natural resistance, unlike spectinomycin resistance observed 
in most monocots or spontaneous point mutation of the 16 
S rRNA gene observed during the selection process. In 
addition, kanamycin is not in human clinical use as an 
antibiotic and several crops containing kanamycin resistant 
60 nuclear transgenes have been already approved by FDA for 
human consumption (e.g. flavor savor tomatoes) and cur-
rently in the market place. 
As shown in FIG. 24, in this non-limiting example, all 
transgenes are regulated by the plastid Prrn promoter; this 
65 l 6S rRNA promoter drives the entire rRNA operon in the 
native chloroplast genome and contains binding sites for 
both the nuclear encoded and plastid encoded RNA poly-
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merases. Therefore, this promoter is capable of functioning 
in both proplastids and chloroplasts (green and non-green, in 
the light and dark). The aphA-6 gene is further regulated by 
the gene 10 5'UTR capable of efficient translation in the 
dark, in proplastids present in non-green tissues (see GFP 5 
expression in proplastids of non-green cells of corn and 
carrot in FIGS. 19 and 23 regulated by the 16S rRNA 
promoter and gene 10 UTR). The rps16 3'UTR has been 
used to stabilize aphA-6 gene transcripts. The aphA-2 (nptII) 
gene, on the other hand is regulated by the psbA promoter, 10 
5' and 3' UTRs, which are light regulated and highly efficient 
in the light, in chloroplasts (see A. Fernandez-San Millan, A. 
Mingeo-Castel, M. Miller and H. Daniell, 2003, A chloro-
plast transgenic approach to hyper-express and purify 15 
Human Serum Albumin, a protein highly susceptible to 
proteolytic degradation. Plant Biotechnology Journal, in 
press; also see WO 01/72959). Therefore, a combination of 
both aphA-6 and aphA-2 genes, driven by regulatory signals 
in the light and in the dark in both proplastids and chloro- 20 
plasts, provides continuous protection for transformed plas-
tids/chloroplasts around the clock from the selectable agent. 
The gene(s) of interest with appropriate regulatory signals 
(gene X) are inserted downstream or upstream of the double 
barrel selectable system. Because multiple genes are 25 
inserted within spacer regions (DeCosa et al 2001, Daniell 
& Dhingra, 2002), the number of transgenes inserted does 
not pose problems in transcription, transcript processing or 
translation of operons (WO 01/64024). In a variation of this 
example, aphA-6 and aphA-2 genes, coupled with different 30 
transgenes are inserted at different spacer regions within the 
same chloroplast genome using appropriate flanking 
sequences and introduced via co-transformation of both 
vectors. 
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Particle Bombardment of Embryogenic Calli 
Micro projectiles were coated with DNA (pDA34-ZM-
gfp-BADH and pDA33-ZM-aadA-BADH) and bombard-
ment was carried out with the biolistic device PDSlOOO/He 
(Bio-Rad). 
Prior to bombardment, embryogenic calli were selected, 
transferred over sterile filter paper (Watman No. 1), and 
placed on the surface of a fresh medium in standard Petrti 
plates (100x15 mm). Gold particles (0.6 µm) were then 
coated with plasmid DNA as follows: 50 µI of washed gold 
particles were mixed with 10 µI DNA (1 µg/µl), 50 µI of 
2.5M CaCl2 , 20 µI of O.lM spermidine and vortexed. 
Particles were cneterfuged for a few seconds at 3000 rpm 
and then the ethanol was poured off. Ethanol washing was 
repeated five times, then the pellet was resuspended in 30 µI 
of 100% ethanol and placed on ice until it was used for 
bombardment (the coated particles were used within 2 
hours). Bombardment was carried out with the biolistic 
device PDSlOOO/He (Bio Rad) by loading the target sample 
at level 2 in the sample chamber under a partial vacuum (28 
inches Hg). 
The callus cultures were bombarded with the maize 
chloroplast transformation vectors using 1100 psi rupture 
discs. Following bombardment, the explants were trans-
ferred to a fresh medium; plates were sealed with micropore 
tape and incubated in darkness at 25-28° C. 
Selection 
Selection was intiated two days after bombardment. The 
bombarded calli were transferred to callus induction 
medium containing 5-20 mM BA (betaine aldehyde) or 
25-100 mg/I streptomycin. Selection was also carried out 
using 50-150 mM NaCl in combination with the BA to 
maintain osmostic pressure. 
35 Regeneration 
Example 7 Regeneration was initiated 6 to 8 weeks after bombard-
ment by transferring the calli to a medium Rl containing Ms 
salts and vitamins supplemented with 1.0 mg/I NAA 
(a-naphthalene acetic acid), 2% sucrose, 2 g/l myoinositol Genetic Engineering of the Corn and Ryegrass Chloroplast Genomes 
A. Transformation of Corn Chloroplast Genome 
For genetic engineering of the corn chloroplast genome, 
corn specific sequences, flanking the targeted integration site 
in the corn chloroplast genome (trnI and trnA) were ampli-
fied with specific PCR primers and subcloned to flank the 
betaine aldehyde dehydrogenase (BADH) selectable marker, 
and green fluorescent protein (GFP) reporter gene expres-
sion cassette. 
40 and 0.3% phytagel at pH 5.8. Regenerated plants were 
transferred to R2 containing 1h MS salts and vitamins, 3% 
sucrose and 0.3% phytagel at pH 5.8. Regenerated plants 
were maintained in light (16/8 hr photoperiod). 
45 
Shoot Multiplication 
The Surface Steriliztion and Germination of Corn Seeds 
Corn seeds were surface sterilized in a solution containg 
2.6% Sodium hypochlorite (prepared from commercial 
bleach) containing 0.1 % Tween 20 for 20 minutes under 
Callus cultures were initiated from aseptically excised 
immature zygotic embryos (1-2 mm in length), produced on 
self-pollinated ears of Hill (Fl) maize plants. Ears were 
surface sterilized in a solution containing 2.6% Sodium 
hypochlorite (prepared with commercial bleach) containing 
0.1%Tween20 (polyoxyethylene sorbitan monolaurate) for 
50 continuos shaking, then rinsed four times in sterile distilled 
water. Seeds were grown on MS medium at pH 5.8 in 
darkness. Nodal sections were excised aseptically from three 
day old seedlings. The nodal sections appear as clear demar-
cations on the germinated seedlings and represent the sev-
55 enth node. When excised, the nodal cross sections are 1.3 to 
1.5 mm in length. 20 miniutes under continuous shaking, then rinsed 4 times in 
sterile distilled water. The Embryos were then placed on the 
callus induction medium CI-1, which contained N6 salts and 
vitamins (463.0 mg/I (NH4 ) 2S04 , 2830.0 mg/IKN03 , 400 
mg/I KH2P04 , 166.0 mg/I CaCl2 , 185 mg/I MgS04 .7H2 0, 60 
37.3 mg/I Na2 -EDTA, 27.85 mg/I FeS04 .7H20, 1.6 mg/I 
H3 B03 , 4.4 mg/I MnS04 .H20, 0.8, KI, 1.5 mg/I 
ZnS04 .7H2 0), 2% sucrose and 1.0 mg/I 2,4- (2,4 dichloro-
phenoxy acetic acid), with the rounded scutellar side 
exposed and the flat plumule-radicle axis side in contact 65 
with the medium. Callus cultures were maintained in dark-
ness at 25-28° C. and subcultured every two weeks. 
Particle Bombardment of Nodal Sections 
Prior to bombardment, 20-30 nodal sections were placed 
in the center of each petri plate with acropitila end up. 
Bombardment was carried out with the maize chloroplast 
vectors, using 1100, 1300 and 1550 psi rupture discs. 
Multiple Shoot Induction and Selection 
Nodal section explants are placed acropital end up on 
shoot multiplication medium SM! composed of Ms salts and 
vitamins, 1.0 mg/I 6BA (6-Benzyl amino purine), 3% 
sucrose and 5 g/l phytagel at pH 5.8 under continuous light 
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at 25° C. Initiation of the shoot-tip clumps from the original 
shoot tips occurred 2 to 4 weeks after culture. Two days after 
bombardment, transformed nodal sections were transferred 
to shoot multiplicaton medium containing 5-20 mM BA or 
50-100 mg/I streptomycin selective agents. Subsequent sub-
cultures at two week intervals were carried out by selecting, 
dividing and subculturing green clumps on selective shoot 
multiplication medium containing 5-20 mM BA or 25-100 
mg/I streptomycin. 
Regeneration 
The Multiple shoot clumps were regenerated by transfer-
ring them to regeneration medium Ml containing MS salts 
and Vitamins, 5 mg/I IBA and 3% sucrose at pH 5.8. The 
developed shoots were regenerated by transferring the shoot 
tip clumps to M2 medium containing 1h MS salts and 
vitamins, 3% sucrose and 3 g/l phytagel at pH 5.8. It should 
be further mated that all the regeneration media are supple-
mented with 5-20 mM BA or 25-100 mg/I streptomycin as 
the selective agents. 
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genome, it is preferred to use the light regulated psbA 
promoter/UTR or 16 S rRNA promoter/gene 10 UTR, 
respectively. 
B. Ryegrass Chloroplast Transformation 
Annual ryegrass chloroplast transformation vector facili-
tates the integration of transgene into the inverted repeat 
(IR) region of the annual ryegrass chloroplast genome. The 
vector pLD-Ryegrass-BADH contains the chimeric aadA 
gene and the BADH gene driven by the constitutive 16 S 
10 rRNA promoter and regulated by the 3'UTR region of psbA 
gene from petunia plastid genome. In this construct both, 
aadA and BADH possess the chloroplast preferred riboso-
mal binding site, GGAGG. Another vector used for ryegrass 
chloroplast transformation pLD-ryegrass-UTR-BADH has 
15 the constitutive 16 S rRNA promoter driving the expression 
of the dicistron, but BADH is under the regulation of the 
promoter and the 5'UTR of the psbA gene and the 3'UTR of 
psbA gene, for enhanced expression. When green tissue or 
non-green embryogenic calli are used for introducing the 
20 transgene into the com chloroplast genome, it is preferred to 
use the light regulated psbA promoter/UTR or 16 S rRNA 
promoter/gene 10 UTR, respectively. To engineer the com chloroplast genome free of antibiotic 
resistance genes, maize calli were bombarded with a chlo-
roplast expression vector containing the green fluorescent 
protein (GFP) and the betaine adehyde dehydrogenase 25 
(BADH) genes as selectable or screenable markers. To 
compare the betaine aldehyde (BA) selection with strepto-
mycin, another chloroplast expression vector was con-
structed containing the aada and the BADH genes. The 
number of putative transgenic events was higher on BA 
selection than on streptomycin. Transgenic com tissues 
screened on BA were examined using a laser-scanning 
confocal microscope. The GFP fluorescence was observed 
throughout the somatic embryos of corn. Chloroplast trans-
formation of com provides a suitable avenue for the pro-
duction of edible vaccines and oral delivery of biopharma-
ceuticals. 
Vectors for Production of Edible Anthrax Vaccine in 
Transgenic Chloroplast of Com or Ryegrass: 
Studies have confirmed the role of PA as the major 
protective antigen in the humoral response but also indicate 
a significant contribution of LF and EF to immunoprotec-
tion. The LF amino terminal domain, amino acid residues 
1-254 (27 kDa) contains all the information necessary for 
30 binding PA and mediating translocation, and this domain 
alone is nontoxic because the catalytic domain of LF, 
residues 255-776, is responsible for lethality. Titers of 
antibody to both PA and LF from mice immunized with the 
combination were 4 to 5 times greater than titers from mice 
35 immunized with either alone. Therefore we express the 
constructs LF27-PA63 (PA63 is the cleaved active form of 
PA), CTB-LF27 fusion proteins, and LF27 and PA indepen-
dently within the same edible plant as a standard. The 
LF27-PA63 and CTB-LF27 constructs are expressed alone Com Chloroplast Transformation Vector 
Corn chloroplast transformation vector facilitates the inte-
gration of transgene into the inverted repeat (IR) region of 
the corn chloroplast genome. The vector pLD-Com-BADH 
contains the chimeric aadA gene and the BADH gene driven 
by the constitutive 16 S rRNA promoter and regulated by the 
3'UTR region of psbA gene from petunia plastid genome. In 
this construct both, aadA and BADH possess the chloroplast 
preferred ribosomal binding site, GGAGG. Another vector 
used for com chloroplast transformation pLD-corn-UTR-
BADH has the constitutive 16 S rRNA promoter driving the 
expression of the dicistron, but BADH is under the regula-
tion of the promoter and the 5'UTR of the psbA gene and the 
3'UTR of psbA gene, for enhanced expression. Since the 
expression of the foreign protein is desired in chromoplasts 
of corn seeds, the gene of interest needs to be under the 
control of a regulatory sequence that is free from cellular 
control. In this context, examples of suitable candidate 
regulatory sequences are the T7 gene 10-leader sequence 
and cry2Aa2 UTR. The T7 gene 10-leader sequence is used 
40 and together as an operon in corn and ryegrass. It has been 
demonstrated that Rotavirus enterotoxin proteins fused with 
CTB is processed via the MHC II pathway generating a 
strong T-cell response. Thus CTB-fusion proteins produced 
in plants are ideal for oral delivery. By expressing the 
45 CTB-LF27 and PA-LF27 we maximize immunity to lethal 
toxin challenge. This is because both Gml ganglioside and 
anthrax toxin receptor (ATR) can be bound by ligands and 
work synergistically for maximum immune response. A 
flexible hinge was introduced between fusion proteins to 
50 reduce steric hindrance. Specifically a glycine-proline-gly-
cine-proline hinge between CTB-LF27 and proline-glycine-
proline-glycine hinge between LF27-PA63 was used. The 
application of less frequently used codons in plants within 
the hinge peptide promotes translational arrest during the 
55 protein elongation process, facilitating subunit folding prior 
to translation. The efficiency of folding of some proteins is 
increased by controlled rates of translation in vivo. 
Chloroplast Transformation Protocol for Com and 
Ryegrass: 
Using either immature embryos (IEs) or embryogenic 
callus derived from IEs as a target for biolistic gene transfer 
is a well-established procedure for stable integration into the 
nuclear genome of com or ryegrass. For biolistic transfer of 
integrative chloroplast expression vectors, the gene transfer 
to express foreign proteins in transgenic chromoplasts. The 
cry2Aa2 UTR has been shown by the inventor to accumulate 60 
as much foreign protein in chromoplasts as efficient as the 
psbA UTR in green tissues. Therefore the selectable marker 
for additional vectors use the BADH gene under the regu-
lation of psbA promoter and 5'UTR, as psbA is one of the 
most efficiently translated chloroplast genes in green tissues. 
When green tissue or non-green embryogenic calli are used 
for introducing the transgene into the com chloroplast 
65 protocol is adjusted and smaller particle sizes (0.6 µm 
diameter) are used. Microprojectiles are coated with plasmid 
DNA (chloroplast vectors) and bombardments are carried 
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ried out in mature leaves of chloroplast or mature seeds 
amyloplasts of transgenic plants to detect inclusion bodies 
according a protocol and similar to several published elec-
tron micrographs of transgenic chloroplasts, with immu-
out with the biolistic device PDSlOOO/He (Bio-Rad) as is 
well-known in the art relating to the use of the "gene-gun." 
Expression levels from chloroplast regulatory sequences and 
the size of the proplastids are limiting factors for the 
successful chloroplast transformation using non-green, 
embryogenic callus tissues as a target for the gene transfer. 
Therefore, it is most desirable, when using the present 
invention with plant species not tested here, to compare 
green shoot meristematic cultures with non-green embryo-
genic callus as target tissue for chloroplast transformation. 
Protocols for the establishment of these tissue types are 
reported for com and the grasses and are established in the 
Alpeters laboratory at University of Florida at Gainesville 
for ryegrass. 
5 nogold label of foreign proteins. The PA protein is then 
purified using a two step protocol, such as that described in 
Ahuja, N., Kumar, P., & Bhatnagar, R. (2001), Rapid Puri-
fication of Recombinant Anthrax-Protective Antigen under 
Nondenaturing Conditions, Biochemical and Biophysical 
10 Research Communications, 286, 6-11. The protein is puri-
fied on AKTA-FPLC using anion exchange Resource Q 
colurmi (Pharmacia). The protein is then eluted from the 
colurmi with a 20 ml decreasing gradient of annnonium 
sulphate. Fractions of 1 ml each are collected, analyzed on 
The timing of gene transfer after culture initiation and the 
duration and level of selection affect transgenic events while 
reducing the number of chimeric plants and achieving 
homoplasmy and are best evaluated empirically. BADH and 
aadA selectable markers are compared with the correspond-
ing selective agents. Selection is to be maintained during the 
regeneration process of plants. Regenerated plants are then 
analyzed by PCR and Southern blot for integration in the 
corn or ryegrass plastome. 
15 SDS-PAGE, and those containing PA are pooled. With an 
affinity tag, the PA protein can optionally be purified using 
metal-chelate affinity chromatography under denaturing 
conditions. Ten ml of each fraction is then analyzed on 12% 
SDS-PAGE. Fractions containing the protein are collected, 
20 pooled, and dialyzed against 10 mM Hepes buffer containing 
50 mM NaCl and stored frozen at - 70° C. in suitable 
PCR is done using DNA isolated from control and trans-
genic plants in order to distinguish a) true chloroplast 25 
transformants from mutants and b) chloroplast transfor-
mants from nuclear transformants. In order to test chloro-
plast integration of the transgenes, the 3' primer will anneal 
to the selectable marker gene while the 5' primer will anneal 
to the native chloroplast genome. No PCR product is 30 
expected with nuclear transgenic plants or mutants using this 
set of primers. This screening is essential to eliminate 
mutants and nuclear transformants. Total DNA from wild-
type and transgenic plants is isolated and used as a template 
for PCR reactions. Southern blots allow one skilled in the art 35 
aliquots. 
Recombinant PA proteins are then assayed for their func-
tional activity in the J774Al (American Type Culture Col-
lection) macrophage lysis assay. Varying concentrations of 
PA protein along with LF (1 mg/ml) are added to the cells. 
The native PA along with LF is kept as the positive control. 
After 3 h, cell viability is determined using the MTT 
(3-( 4,5-dimethyl thiazol-2-yl),-5-diphenyltetrazolium bro-
mide) dye and the resulting precipitate is dissolved in a 
buffer containing 0.5% (w/v) sodium dodecyl sulfate, 25 
mM HCl in 90% isopropyl alcohol. Absorption at 540 nm is 
measured and percent viability determined. 
PA can be tested for susceptibility to cleavage by trypsin. 
To do so, the PA protein (1.0 mg/ml) is incubated with 
trypsin (1 ng/mg of protein) for 30 min at room temperature 
in 25 mM Hepes, 1 mM CaC12, 0.5 mM EDTA, pH 7.5. The 
digestion reaction is stopped by adding PMSF to a concen-
tration of 1 mM. Trypsin nicked PA (1.0 mg/ml) is incubated 
40 with LF (1.0 mg/ml) and in 25 mM Tris, pH 9.0, containing 
2 mg/ml CHAPS (3-{ (3-cholamidopropyl) dimethyl ammo-
nia }-propanesulfonic acid) for 15 min at room temperature. 
Samples are applied to nondenaturing 4.5% polyacrylamide 
to determine the copy number of the introduced foreign gene 
per cell as well as to test homoplasmy. There are several 
thousand copies of the chloroplast genome present in each 
plant cell. When foreign genes are inserted into the chloro-
plast genome, not all chloroplasts will integrate foreign 
DNA resulting in heteroplasmy. To ensure that only the 
transformed genome exists in transgenic plants (ho-
moplasmy ), the selection process is continued. In order to 
confirm homoplasmy at the end of the selection cycle, total 
DNA from transgenic plants is probed with the chloroplast 45 
border (flanking) sequences (the trnI-tmA fragment). Wild 
type fragment size is observed along with the larger frag-
ments of transformed plastomes. Presence of a large frag-
ment (due to insertion of foreign genes within the flanking 
sequences) and absence of the native small fragment con- 50 
firms homoplasmy. The copy number of the integrated gene 
is determined by establishing homoplasmy for the transgenic 
chloroplast genome. 
Generate Transgenic Ryegrass and Com Plants Express-
ing an Edible Anthrax Vaccine and Characterize Transgene 55 
Integration and Expression 
Using the aforementioned transformation protocols, vec-
tors for the production of an orally administrable form of PA 
are introduced in ryegrass and com plants. Site specific 
vector integration into the ryegrass or corn plastome is then 60 
confirmed by PCR and Southern blot analysis as specified. 
Western blot verification of PA verifies that recombinant 
anthrax protective antigen proteins are antigenically similar 
gel. 
The binding of PA protein to cell surface receptor is 
analyzed in 24 well plates using constant amount of radio-
iodinated native PA (0.1 mg/ml). J774A.1 (ATCC) cells are 
washed twice with cold HBSS for 5 minutes each time and 
then placed on ice. The medium is replaced with cold 
binding medium (DMEM, Dulbecco's Modified Eagle 
Medium, without sodium bicarbonate containing 1 % bovine 
serum albumin and 25 mM, Hepes, pH 7.4). The cells are 
incubated with 0.1 mg/ml of iodinated PA and varying 
concentrations of the recombinant PA protein at 4° C. for 3 
h and then washed with cold HBSS. The cells are then 
dissolved in 0.1 N NaOH and radioactivity measured in 
Gamma counter. 
Leaves from transgenic lines producing epitope tagged 
products are frozen and powdered at 4 ° C. using a micro-
dismembranator and proteins are extracted in PBS with 1 % 
Triton X-100. Fusion proteins are purified by affinity chro-
matography on a nickel-agarose bed, using standard 6-His 
methods, as described above. 
to native PA using monoclonal antibodies against PA (Ad-
vanced ImmunoChemical GI-Bal). PA is quantified by a 
ELISA using purified PA antigen as standard and commer-
cially available antibody. Electron microscopy is next car-
Assessment of Immunogenic Properties of Transgenic 
65 Plant-derived PA: 
Com and ryegrass expressing PA as potential edible 
vaccines against anthrax are characterized using the protocol 
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described above. These are then evaluated for the ability of 
PA-expressing com seeds or corn or ryegrass leaves or bay 
to function as edible vaccines for the induction of serum and 
mucosa! (bronchial lavage, nasal, vaginal, and fecal) anti-
bodies by ELISA. Antibodies induced by feeding the trans- 5 
genie com or ryegrass to mammals neutralize the biologic 
activity of anthrax lethal toxin. This activity can be con-
firmed in an in vitro macrophage cytotoxicity assay. Anti-
body responses in mice and humans following ingestion of 
transgenic potatoes and com expressing recombinant bac- 10 
terial proteins have been successfully demonstrated. 
Oral immunization of mice and other manmials by feed-
ing transgenic plants or plant parts is accomplished as 
follows. In the case of com and ryegrass, female BALB/c 
mice are fed transgenic com or ryegrass, control corn or 15 
ryegrass, or soluble rPA in conjunction with the mucosa! 
adjuvant LT(R192G). The amount of rPA fed to control 
animals is based upon the amount of PA in the transgenic 
corn or ryegrass fed to the animals. That amount correlates 
with the amount of transgenic com or ryegrass a mouse will 20 
consume in a one hour period. Mice tend to eat grass if a 
small amount of vanilla extract is placed on each leaf. Two 
additional groups can be included in which the mucosa! 
adjuvant LT(Rl 92G) is administered in conjunction with the 
transgenic or control corn or ryegrass. Edible vaccines 25 
administered to mice often require the presence of a mucosa! 
adjuvant due to the small amount of material that can be 
consumed by a mouse. However, this is not necessary when 
using the plants of the present invention to vaccinate 
humans, or other large mammals due to the volume which 30 
can be consumed by the animal. Twenty-five micrograms of 
the adjuvant should be applied directly to the com or 
ryegrass before consumption when testing mice. 
Intranasal immunization is accomplished in mice as fol-
lows. Mice are first lightly anesthetized with Isoflurane for 35 
approximately 45 seconds. The immunizing inoculum (5-10 
ml per animal/per dose) is delivered intranasally to the 
external nares of one nostril with a pipette tip. 
Oral immunization: Oral inoculations consisted of 500 ml 
of the antigen preparation in saline delivered intragastrically 40 
with a blunt-tip feeding needle (Popper & Sons, Inc.). 
28 
carried out at room temperature. After blocking with 1 % 
BSA, twofold serial dilutions of serum, BAL, nasal wash, 
vaginal wash, or fecal extract from the experimental animals 
are added. Alkaline phosphatase conjugated rabbit anti-
mouse IgG or anti-mouse IgA are used for determination of 
total IgG or IgA. Biotinylated anti-mouse IgGl, IgG2a, 
IgG2b or IgG3 followed by alkaline phosphatase conjugated 
streptavidin are used to quantify antibody isotypes. Optical 
density at 405 nm is determined using an ELISA reader. 
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<160> NUMBER OF SEQ ID NOS, 2 
<210> SEQ ID NO 1 
<211> LENGTH, 4 
<212 > TYPE, PRT 
SEQUENCE LISTING 
<213> ORGANISM, Bacillus anthracis 
<400> SEQUENCE, 1 
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39 40 
-continued 
Arg Lys Lys Arg 
1 
<210> SEQ ID NO 2 
<211> LENGTH, 3 
<212> TYPE, PRT 
<213> ORGANISM, Bacillus anthracis 
<400> SEQUENCE, 2 
Phe Phe Asp 
1 
What is claimed is: 
1. A plastid transformation vector for stably transforming 
a plastid, said plastid vector comprising, as operably linked 
components, a first flanking sequence, at least one regulatory 
sequence operable in a plastid, a DNA sequence coding for 
a protective antigen, a DNA sequence coding for a chap-
eronin, and a second flanking sequence. 
2. A plastid transformation vector for stably transforming 
a plastid, said plastid vector comprising, as operably linked 
15 
components, a first flanking sequence, at least one regulatory 
sequence operable in a plaslid, a DNA sequence coding for 
a protective antigen, a DNA sequence coding for a chap-
20 eronin, and a second flanking sequence, wherein said pro-
tective antigen is a bacterial antigen. 
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